Why hold for a year to find out if the drug works or not. Even the much-maligned Seralaxin passed the dyspnea test in acute setting. Results were mediocre but don't expect to hear that from the pumpers here.
If you don't want to wait for drug trial results sounds like investing in biotech companies may not be your thing. Seralaxin failed on numerous secondary endpoints and a primary endpoint. It included over 1000 patients so not real comparison with OM trial which only have 200 individuals in the therapeutic dose cohort.